Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non‐small cell lung cancer

Limited treatment options are available for stage IIIB/IV non‐small cell lung cancer (NSCLC). Nivolumab, a programmed cell death‐1 immune checkpoint inhibitor antibody, has been shown to be effective for the treatment of NSCLC. The present study investigated the effectiveness and safety of nivolumab...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Sci
Hlavní autoři: Hida, Toyoaki, Nishio, Makoto, Nogami, Naoyuki, Ohe, Yuichiro, Nokihara, Hiroshi, Sakai, Hiroshi, Satouchi, Miyako, Nakagawa, Kazuhiko, Takenoyama, Mitsuhiro, Isobe, Hiroshi, Fujita, Shiro, Tanaka, Hiroshi, Minato, Koichi, Takahashi, Toshiaki, Maemondo, Makoto, Takeda, Koji, Saka, Hideo, Goto, Koichi, Atagi, Shinji, Hirashima, Tomonori, Sumiyoshi, Naoki, Tamura, Tomohide
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2017
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5448646/
https://ncbi.nlm.nih.gov/pubmed/28266091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13225
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky